<DOC>
	<DOC>NCT01740336</DOC>
	<brief_summary>This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer.</brief_summary>
	<brief_title>A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female adult patients Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or nonmeasurable locally recurrent or metastatic disease Human epidermal growth factor receptor 2 (HER2)negative and HR (estrogen receptor and/or progesterone receptor)positive disease as defined by local guidelines Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Adequate hematologic and end organ function Women of childbearing potential must agree to remain abstinent or to use two adequate methods of contraception, including at least one method with a failure rate of &lt; 1% per year, during the treatment period and for at least 30 days after the last dose of study treatment or 6 months after discontinuation of paclitaxel, whichever is longer Prior noncapecitabine chemotherapy for locally recurrent or metastatic disease Prior treatment with a PI3K inhibitor for advanced or metastatic breast cancer History of intolerance to a taxanecontaining therapy History of clinically significant cardiac or pulmonary dysfunction History of malabsorption syndrome or other condition that would interfere with enteral absorption Clinically significant history of liver disease Active autoimmune disease or active inflammatory disease Immunocompromised status Need for current chronic corticosteroid therapy Pregnancy, lactation, or breastfeeding Current severe, uncontrolled systemic disease Known untreated or active central nervous system (CNS) metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>